INS and Hypoglycemia: Several meta-analyses showing that CSII does not increase the risk of adverse events (maybe with the exception of diabetic ketoacidosis), additionally, and some researches also suggested that a reduction in the incidence of hypoglycemia with pump use compared to MDI (6–10).Although the use of insulin pumps for intensive insulin therapy among patients with T1DM has substantially increased in several developed countries (11), CSII has not been widely used in China (12).